PUBLIC COMPANY
save$ACIUAC Immune SA
$ACIU1015 Lausanne, CHupdated 21d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants
- phase2A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
- phase2A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
- EP1[18F]ACI-15916 PET in α-synucleinopathies
- EP1[18F]ACI-19626 PET in TDP-43 Proteinopathies
- phase2A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 15, 26BUYPfeifer Andrea· Chief Executive Officer$31K↗
🐶 Hiring Signal
News
- Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialPlus news about AC Immune, Lilly's Adverum and SiranBio. 🤝 Eli Lilly signs vaccine deal with Amplitude: The companies will work to develop vaccines using “trans-amplifying RNA,” or taRNA, for infe…endpoints · 12h ago
- Andrea Pfeifer ends 23-year reign at AC Immune; Acadia's top R&D exec announces retirementAC Immune will be searching for a new CEO for the first time, as the company announced this week that Andrea Pfeifer plans to retire after 23 years at the helm. ...endpoints · 3mo ago
- Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BAssertio’s latest offer represents a roughly 31% premium over an initial acquisition proposal. Elsewhere, Kyverna is readying a first-of-its-kind approval application and AC Immune is swapping CEOs.biopharma_dive · 3mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that